Form 4: Camp4 CMO Yuri Maricich Granted 190,000 Stock Options

Camp4 Therapeutics' Chief Medical Officer, Yuri Maricich, was granted 190,000 stock options with an exercise price of $6.01, vesting over three years.

Summary

• Yuri Maricich, Chief Medical Officer of Camp4 Therapeutics Corp, acquired 190,000 stock options.
• The options have an exercise price of $6.01 per share.
• The transaction date for the grant was December 11, 2025.
• The options expire on December 10, 2035.
• Vesting begins on December 1, 2025, with one-third (33.33%) vesting on the first anniversary and the remainder vesting in equal monthly installments over the subsequent 24 months, contingent on continued service.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive signal for management alignment and retention, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 190,000 stock options to the Chief Medical Officer aligns management's interests with shareholder value creation.
• The vesting schedule incentivizes long-term commitment and performance from a key executive.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• The value of the stock options is contingent on the future performance of Camp4 Therapeutics' stock price exceeding the $6.01 exercise price.
• The options are subject to a vesting schedule, meaning the executive must remain employed for the options to fully vest.

Future Outlook

The vesting schedule for the stock options, extending over three years from December 2025, indicates an expectation of continued service and contribution from the Chief Medical Officer to the company's future success.

Industry Context

This stock option grant is a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key talent by linking their financial incentives to the company's long-term performance.

Related Party Transactions

• The grant of stock options to Yuri Maricich, the Chief Medical Officer, constitutes a related party transaction as it involves an executive of the issuer.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of executive interests with shareholder value.
• Employees: Retention and motivation of a key executive (Yuri Maricich).

Next Steps

• Continued service by the Chief Medical Officer to facilitate vesting of the options.
• Potential exercise of options by Yuri Maricich upon vesting and if the stock price is favorable.

Key Dates

Keywords

Camp4 Therapeutics, CAMP, Yuri Maricich, Chief Medical Officer, Stock Options, Insider Transaction, Form 4, Executive Compensation, Equity Grant, Vesting